Deerfield Management’s Passage Bio PASG Stock Holding History

Deerfield Management’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-33,518	Closed	-$10.6M	–	98
2020 Q1	$10.6M	Buy	+33,518	New	+$10.5M	0.34%	64

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Deerfield Management's PASG Position: Q2 2020 in Review

Deerfield Management sold out of Passage Bio (PASG) in Q2 2020, closing a stake of 33,518 shares — an estimated $10.6M sold.

Deerfield Management first reported a position in PASG in Q1 2020 and held it in 1 quarter. The position peaked at $10.6M in Q1 2020. 66 funds tracked by Wall St. Rank hold PASG as of Q2 2020.

Deerfield Management reported no remaining Passage Bio position as of Q2 2020 after selling out during the quarter.
Deerfield Management sold 33,518 Passage Bio shares in Q2 2020, an estimated $10.6M.
Deerfield Management first reported a position in Passage Bio in Q1 2020 and held it in 1 quarter.
Deerfield Management's Passage Bio position peaked at $10.6M in Q1 2020.
66 funds tracked by Wall St. Rank held Passage Bio as of Q2 2020.

Based on Deerfield Management's 13F filing for Q2 2020, filed 14 Aug 2020.